NEW YORK — Unstable retinal thickening may contribute to substandard visual outcomes during anti-VEGF treatment, according to a speaker here.
“As we are all aware, apart from the inconsistency of retinal fluid, variability in foveal thickness during anti-VEGF treatment is associated with worse visual outcomes,” Yodpong Chantarasorn, MD, said at the American Society of Retina Specialists annual meeting.
Chantarasorn and colleagues conducted a retrospective cohort study at five tertiary hospitals between January 2016 and December 2018 to determine predictive biomarkers